Origin and chemical structure
The drug acarbose, which is the main representative of alpha-glucosidase inhibitors, has an interesting biological origin. Chemically, this substance is a complex carbohydrate—an oligosaccharide (more specifically, a tetrasaccharide).
It is obtained not via classical chemical synthesis, but through biotechnological methods: the drug is isolated during the targeted fermentation of specific microorganisms known in microbiology as Actinoplanes utahensis.
Sites of action and mechanism of action
The main task of alpha-glucosidase inhibitors is to prevent the absorption of glucose in the gastrointestinal tract. The mechanism of action is based on the reversible inhibition of key digestive enzymes. The drug has two main sites of action:
- Inhibition of pancreatic $\alpha$-amylase: the initial stage of digestion is blocked, namely the breakdown of complex dietary polysaccharides into disaccharides.
- Inhibition of intestinal membrane-bound $\alpha$-glucosidase: the next stage is stopped—the breakdown of disaccharides into final monosaccharides.
As a result of this dual enzymatic blockade, the formation of monosaccharides directly in the intestinal lumen is severely impaired. The carbohydrate absorption process is significantly slowed down and reduced.
Pharmacological effects and place in therapy
The key clinical effect of acarbose is the reliable reduction of postprandial hyperglycemia—the sharp spike in blood sugar levels that predictably occurs after a meal.
It is important to note that the drug does not cause pronounced hypoglycemia. This is because alpha-glucosidase inhibitors do not stimulate the secretion of endogenous insulin by the pancreas, but merely modulate the process of nutrient absorption from food.
In clinical practice, the agent is most often prescribed as part of combination therapy along with other oral hypoglycemic drugs. For the drug to work correctly, the dosing regimen requires taking it strictly before meals.
Side effects and their pathogenesis
The main pool of adverse events associated with acarbose intake is related to dyspeptic disorders. Patients most frequently complain of flatulence (occurring in 20–30% of patients) and abdominal pain. Diarrhea occurs much less frequently (in about 3% of cases).
The pathogenesis of these side effects directly stems from the drug's mechanism of action:
- Due to the enzyme blockade, unabsorbed carbohydrates cannot be absorbed and remain in large quantities in the lumen of the small intestine.
- This carbohydrate mass becomes an excellent nutrient medium for the local intestinal microflora.
- The active process of sugar fermentation by bacteria begins.
- During fermentation, an excessive amount of gas is released, which leads to bloating, pain, and discomfort.
Contraindications
Considering the mechanism of action and direct effect on the gastrointestinal tract, alpha-glucosidase inhibitors have strict restrictions for use.
They are strictly contraindicated in any conditions accompanied by impaired absorption function (for example, in clinically pronounced malabsorption syndrome). Furthermore, the drug must not be prescribed to patients suffering from inflammatory bowel disease (IBD), as excessive gas production, fermentation, and mucosal irritation can severely aggravate the course of the underlying pathology.
Briefly: answers to topical questions
What are the absolute contraindications for prescribing alpha-glucosidase inhibitors?
Contraindications for prescribing alpha-glucosidase inhibitors include:
- inflammatory bowel disease (IBD);
- malabsorption syndrome — conditions accompanied by impaired absorption function.
What is the oral bioavailability of acarbose?
When taken orally, acarbose is practically not absorbed into the systemic circulation. The drug exerts its pharmacological effect locally, residing directly within the intestinal lumen. Its mechanism of action involves the competitive inhibition of the alpha-glucosidase enzyme in the small intestine, leading to a slowed and reduced absorption of glucose from dietary carbohydrates.
To easily remember the mechanism of acarbose side effects, imagine a "bacterial feast": carbohydrates were not absorbed, remained in the small intestine, and the local microflora turned them into a gas factory (fermentation).
Class and exam questions
Why do alpha-glucosidase inhibitors not cause severe hypoglycemia?
Drugs of this group do not stimulate insulin secretion by the pancreas. Their action is restricted to the intestinal lumen, where they simply slow down carbohydrate absorption, blunting the postprandial glucose peak.
Which specific enzymes does acarbose act on?
The drug reversibly inhibits two key enzymes: pancreatic $\alpha$-amylase (breaks down polysaccharides) and intestinal membrane-bound $\alpha$-glucosidase (breaks down disaccharides).
Where exactly does the fermentation of unabsorbed carbohydrates causing flatulence take place?
Carbohydrates that remain unhydrolyzed due to the drug's action are retained in the lumen of the small intestine, where they undergo active fermentation by the local microflora.
What else to study on this topic
- Biochemical stages of normal dietary polysaccharide breakdown.
- The role of the intestinal microflora in the fermentation of unabsorbed carbohydrates.
- Principles of combination therapy with oral hypoglycemic agents.
- Pathogenesis of malabsorption syndrome and the effect of enzyme inhibitors on it.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Full study guide on "Alpha-glucosidase inhibitors" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Hormone preparations, their synthetic substitutes, and antagonists"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.